Please ensure Javascript is enabled for purposes of website accessibility

Germany Awards $743 Million to BioNTech and CureVac for Coronavirus Vaccine Development

By Todd Campbell - Sep 15, 2020 at 1:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

BioNTech and CureVac will use the new funding to advance COVID-19 research and development in Germany.

To accelerate COVID-19 vaccine development and boost vaccine manufacturing capacity within its borders, the German Federal Ministry of Education and Research is awarding BioNTech (BNTX 1.48%) and CureVac N.V. (CVAC 0.44%) grants worth up to $743 million at current euro-to-U.S. dollar conversion rates.

Specifically, BioNTech can receive up to 375 million euros, or $444 million, to advance its BNT162 vaccine program in collaboration with Pfizer (PFE -1.18%), and CureVac can pocket up to 252 million euros, or $299 million, to continue development of its COVID-19 vaccine program.

A woman in a lab coat speaks through a megaphone.

IMAGE SOURCE: GETTY IMAGES.

Currently, BioNTech and Pfizer are conducting phase 3 trials of BNT162b2 with preliminary results expected in October. If the trial is successful, then the healthcare companies plan to submit applications to regulators for its emergency use. CureVac's COVID-19 program is in phase 1 trials, and data that could allow it to enter phase 3 trials is expected in the fourth quarter.

Previously, BioNTech and Pfizer agreed to provide up to 200 million doses of its vaccine to the European Union beginning later this year if the vaccine wins a regulatory green light. Separately, CureVac says its negotiating with the European Commission to provide up to 225 million doses, plus an option for up to an additional 180 million doses.

The grants are contingent upon the companies achieving development milestones. According to BioNTech, it has already met five of eight requirements.  CureVac anticipates receiving 103 million euros in 2020 and up to 149 million euros in 2021, depending on its successfully meeting its goals.

Todd Campbell owns shares of Pfizer. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
BNTX
$183.11 (1.48%) $2.67
CureVac N.V. Stock Quote
CureVac N.V.
CVAC
$13.76 (0.44%) $0.06
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.27 (-1.18%) $0.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.